BTIG Reiterates Buy on Akebia Therapeutics, Maintains $5 Price Target

Benzinga · 3d ago
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $5 price target.